Skip to content

Catalyzing the Discovery of New Treatments for Proteinopathies

Ncardia author image

By Jessica Koepke

A suite of human-based automated in vitro assays to identify active candidates for protein aggregation quickly and efficiently

  • Purpose-built to increase confidence
  • Designed to deliver robust and reproducible data
  • Formed to catalyze drug discovery

The mis-localization and accumulation of protein aggregates is a shared hallmark for multiple neurodegenerative disorders (NDDs). Production of abnormal proteins is an important driver of Alzheimer’s, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS) as well as other NDDs categorized as proteinopathies. Therefore, finding drugs that can prevent or eliminate the formation of protein aggregates in neurons has the potential to become an effective treatment for more than one proteinopathy.

To help drug developers pursue these types of therapies we have developed the Proteinopathy Exploration Package.
This is a suite of drug discovery assays that recapitulates the aggregation of Tau, α-Syn and TDP-43 in human iPSC-derived neurons and provides clinically relevant readouts to understand the impact of your compounds on both early and late stages of aggregation. With the Proteinopathy Exploration Package your results are ready in 6 weeks. The fully automated assay suite is amenable for 96 and 384 well plate formats. Data analysis is a smooth and quick with our in-house developed algorithms and analytics tools.

01Dec-webinar registration page-1

Fill out the form to watch the replay: